About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Treatment of SARS Caused by COVID-19 With Ruxolitinib

NCT04334044·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Grupo Cooperativo de Hemopatías Malignas

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patients with diagnosed COVID-19 with confirmatory test
Increase in work of breathing or presence of dyspnea
Presence of lung changes associated with COVID pneumonia by chest imaging
Informed consent

You may not be if

Pregnancy or breastfeeding
Thrombocytopenia below 20,000 cells/mm3
Neutropenia below 500 cels/mm3
Known and active infection of HIV, Hepatitis C, Hepatitis B, Herpes Zoster or Mycobacterium Tuberculosis

The record

StatusCompleted

PhasePhase 1–2

Taking part77

StartedSep 2020

UpdatedJul 7, 2021

Conditions

COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2

Where1

Grupo Cooperativo de Hemopatías Malignas
Huixquilucan, State of Mexico, Mexico

Clareo Health | Treatment of SARS Caused by COVID-19 With Ruxolitinib